Close Menu

NEW YORK – Adaptive Biotechnologies announced that its ClonoSeq assay is now available in all 50 states, following approval from the New York State Department of Health clinical laboratory evaluation program (CLEP), the firm said in a statement.

The assay received approval from NY State for detection and monitoring of minimal residual disease in patients with B cell blood cancers.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

This webinar will discuss a next-generation sequencing approach for detecting genomic mutations in hematologic maglignancies.


This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.